| DANVERS,
Mass. (June 6, 2006)—ABIOMED, Inc. (NASDAQ: ABMD) announced
today that its technologies to treat heart failure will be included
in eight presentations at the American Society for Artificial Internal
Organs’ (ASAIO) 52nd Annual Conference being held in Chicago
from June 8-10. The ASAIO conference provides presentations from around
the world to a diverse group of medical specialties.
Poster and oral presentations will include:
Thursday, June 8
- “Uni-Ventricular Support Using an Extracardiac Assist
Device,” at 4 pm.
- “Extended Duration of Support on the AB5000 Ventricle
Promotes Survival Outcomes,” from 5-6 pm.
- “Fluid Dynamic Studies of a Polymetric Trileaflet Heart
Valve,” from 5-6 pm.
- “Initial Clinical Experience with the AbioCor Patient
Carried Electronics (PCE) System,” from 5-6 pm.
Friday, June 9
- “Low Pressure Drop Polymeric Trileaflet Heart Valve,”
at 1:45 pm.
- “AbioCor Remote Monitoring,” from 5-6 pm.
Saturday, June 10
- “Clinical Experience with the Smallest Available Right
Ventricular Assist Device: The IMPELLA RECOVER RD,” at 1:45
pm.
- “Development Progress on a Second Generation Total Artificial
Heart,” at 4:45 pm.
ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”)
is a leading developer, manufacturer and marketer of medical products
designed to assist or replace the pumping function of the failing
heart. ABIOMED currently manufactures and sells the AB5000™
Circulatory Support System and the BVS® 5000 Biventricular Support
System for the temporary support of all patients with failing but
potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA®
RECOVER® minimally invasive cardiovascular support systems under
CE Mark approval. The IMPELLA products are not yet available for
sale in the United States. The Company’s AbioCor® Implantable
Replacement Heart was the subject of an initial clinical trial under
an Investigational Device Exemption from the United States Food
and Drug Administration. The AbioCor has not been approved for commercial
distribution, and is not available for use or sale outside of the
initial clinical trial. For additional information please visit:
www.abiomed.com.
Contacts:
Liza Heapes
ABIOMED, INC.
Media Relations
(978) 646-1668
mediarelations@abiomed.com
Daniel Sutherby
ABIOMED, INC.
Chief Financial Officer
(978) 646-1812
ir@abiomed.com
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements
regarding development of ABIOMED’s existing and new products,
the Company’s progress toward commercial growth, and future
opportunities. The Company’s actual results may differ materially
from those anticipated in these forward-looking statements based
upon a number of factors, including uncertainties associated with
development, testing and related regulatory approvals, anticipated
future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological
change, government regulation, future capital needs and uncertainty
of additional financing and other risks and challenges detailed
in the Company’s filings with the Securities and Exchange
Commission, including the Annual Report filed on Form 10-K. Readers
are cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this Release. The
Company undertakes no obligation to publicly release the results
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances that occur after the date
of this Release or to reflect the occurrence of unanticipated events.
###
|
